Advertisement

A new treatment strategy for thrombotic thrombocytopenic purpura in developing countries: A single dose rituximab-contained regimen

      Thrombotic thrombocytopenic purpura (TTP) is characterized by microangiopathic hemolytic anemia and consumptive thrombocytopenia, with or without end-organ damage. Prompt diagnosis and treatment are vital due to its life-threatening severity [
      • Furlan M.
      • Lammle B.
      Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.
      ]. The use of plasma exchange has decreased the mortality rate of TTP from >90 % to <10–30 % [
      • Rock G.A.
      • Shumak K.H.
      • Buskard N.A.
      • et al.
      Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.
      ]. However, relapse of the disease occurs in more than one-third of the cases that achieve remission [
      • Bell W.R.
      Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Furlan M.
        • Lammle B.
        Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.
        Baillieres Clin. Haematol. 1998; 11: 509-514
        • Rock G.A.
        • Shumak K.H.
        • Buskard N.A.
        • et al.
        Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.
        N. Engl. J. Med. 1991; 325: 393-397
        • Bell W.R.
        Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning.
        Semin. Hematol. 1997; 34: 134-139
        • Fakhouri F.
        • Vernant J.P.
        • Veyradier A.
        • et al.
        Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
        Blood. 2005; 106: 1932-1937
        • Zaja F.
        • Battista M.L.
        • Pirrotta M.T.
        • et al.
        Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
        Haematologica. 2008; 93: 930-933
        • Zwicker J.I.
        • Muia J.
        • Dolatshahi L.
        • et al.
        Adjuvant low-dose rituximab and plasma exchange for acquired TTP.
        Blood. 2019; 134: 1106-1109
        • Ni X.
        • Li D.
        • Yuan C.
        • et al.
        Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: a multicenter, randomized, controlled study.
        Am. J. Hematol. 2022; 97: 440-447
        • Scully M.
        • Hunt B.J.
        • Benjamin S.
        • et al.
        Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.
        Br. J. Haematol. 2012; 158: 323-335
        • Scully M.
        • Cataland S.
        • Coppo P.
        • et al.
        Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.
        J. Thromb. Haemost. 2017; 15: 312-322
        • Scully M.
        • McDonald V.
        • Cavenagh J.
        • et al.
        A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.
        Blood. 2011; 118: 1746-1753